REQUEST A DEMO
Total
USD $0.00
Search more companies

Eutilex Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Eutilex Co.,Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Eutilex.Co.,Ltd is a biotechnology company operating within the biopharmaceutical industry, specializing in the development of immunotherapeutic anti-cancer therapies and antibodies. The company focuses on treating malignant diseases, particularly cancer, and claims to use its proprietary 4-1BB platform technology to enhance immune responses against cancer cells.

Headquarters
1401, 25, Gasan Digital 1-Ro, Geumcheon-Gu
Seoul; Seoul;

Contact Details: Purchase the Eutilex Co.,Ltd. report to view the information.

Website: http://www.eutilex.com

Basic Information
Total Employees:
Purchase the Eutilex Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Eutilex Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Eutilex Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Eutilex Co.,Ltd. report to view the information.
Incorporation Date:
February 27, 2015
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
19.1%
Purchase this report to view the information.
16.8%
Purchase this report to view the information.
8.8%
Subsidiaries
Eutilogics Inc
Company Performance
Financial values in the chart are available after Eutilex Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
14.75%
Total operating revenue
32.17%
Operating Profit/Loss (EBIT)
33.19%
EBITDA
36.55%
Net Profit/Loss for the Period
30.98%
Total Assets
-24.52%
Total Equity
-46.26%
Operating Profit Margin (ROS)
114.8%
Net Profit Margin
106.34%
Return on Equity (ROE)
-9.71%
Debt/Equity
41.37%
Quick Ratio
-1.6%
Cash Ratio
-0.96%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?